Key insights
- Adagio Medical received a Nasdaq non-compliance notice for failing to meet the minimum bid price requirement, with its stock closing below $1.00 for 30 consecutive days. The company has until December 9, 2026, to regain compliance, potentially through a reverse stock split. Failure to do so could lead to delisting. This news, coupled with a 'WEAK' Financial Health score, suggests potential downside risk for the stock and highlights broader concerns about smaller-cap companies facing regulatory hurdles.
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) disclosed Friday that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price requirement. According to a statement based on a press release, the company’s common stock has closed below $1.00 per share for the past 30 consecutive business days, which does not meet Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
The notification does not immediately affect the listing or trading of Adagio Medical’s common stock, which will continue to trade on the Nasdaq Capital Market. The company has 180 calendar days from the date of the notice, or until December 9, 2026, to regain compliance. To do so, the closing bid price of the company’s common stock must reach at least $1.00 per share for a minimum of ten consecutive trading days within this period.
If the company does not regain compliance by December 9, 2026, it may be eligible for an additional 180-day compliance period if it notifies Nasdaq of its intention to resolve the deficiency, potentially through a reverse stock split, and meets other listing requirements except for the bid price rule. If the company fails to meet the standards after the second period, Nasdaq may move to delist the company’s common stock.
Adagio Medical stated it is evaluating all available options to regain compliance with the Nasdaq listing rule. There is no assurance that the company will be able to meet the requirements within the given timeframe. According to InvestingPro data, the company has a "WEAK" Financial Health score, and the platform identifies additional challenges facing the medical device maker, with 7 more ProTips available to subscribers.
This information is based on a statement made in a recent SEC filing.
In other recent news, Adagio Medical Holdings has submitted a Premarket Approval application to the U.S. Food and Drug Administration for its vCLAS Ventricular Ablation System. This system is intended to treat drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with specific heart diseases. The company has also received FDA Investigational Device Exemption approval to expand its FULCRUM-VT trial, which will evaluate the next-generation vCLAS Ultra-Low Temperature Ablation System. This device is noted for achieving significantly reduced ablation times in pre-clinical models.
Additionally, Adagio Medical has been the subject of recent analyst activity. Lucid Capital Markets initiated coverage with a buy rating and a price target of $3.00, highlighting the company’s position in an underserved market. Piper Sandler also initiated coverage with an overweight rating, citing the competitive clinical profile of Adagio’s cryoablation technology. The company has also scheduled its 2026 Annual Meeting of Stockholders for June 16, with details to be provided in a forthcoming proxy statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ADGM plus thousands of other stocks and find your next hidden gem with massive upside.